Renova Therapeutics
Biotechnology, El Camino Real Ste 350, San Diego, , 92130, California, 11455, United States, 11-50 Employees
Phone Number: 85********
Who is RENOVA THERAPEUTICS
Founded by pioneers in biopharmaceuticals, Renova Therapeutics is developing a portfolio of definitive gene and peptide therapies to restore health to people suffering from cardiovascular...
Read More
-
Headquarters: 11455 El Camino Real Ste 350, San Diego, California, 92130, United States
-
Date Founded: 2009
-
Employees: 11-50
-
Revenue: Under $1 Million
-
Active Tech Stack: See technologies
-
CEO:
Jack Reich
Email
Phone
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 561110 |
Show More
Does something look wrong? Fix it. | View contact records from RENOVA THERAPEUTICS
Renova Therapeutics Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Renova Therapeutics
Answer: Renova Therapeutics's headquarters are located at El Camino Real Ste 350, San Diego, , 92130, California, 11455, United States
Answer: Renova Therapeutics's phone number is 85********
Answer: Renova Therapeutics's official website is https://renovatherapeutics.com
Answer: Renova Therapeutics's revenue is Under $1 Million
Answer: Renova Therapeutics's SIC: 2834
Answer: Renova Therapeutics's NAICS: 561110
Answer: Renova Therapeutics has 11-50 employees
Answer: Renova Therapeutics is in Biotechnology
Answer: Renova Therapeutics contact info: Phone number: 85******** Website: https://renovatherapeutics.com
Answer: Founded by pioneers in biopharmaceuticals, Renova Therapeutics is developing a portfolio of definitive gene and peptide therapies to restore health to people suffering from cardiovascular and metabolic diseases. Our investigational therapies are based on carefully validated and proprietary research into disease mechanisms and the founders nearly 50 combined years of work in the gene therapy field. This experience enables us to generate an entirely original platform of therapeutics and delivery systems that in a single dose are designed to provide durable, life-long treatments for chronic diseases. Our scientific research, led by Dr. H. Kirk Hammond, appears in numerous peer-reviewed articles that establish the scientific rationale and evidence supporting the development of our pipeline and our novel approach to delivering gene therapies. The first indications the company is pursuing are gene therapy treatments for congestive heart failure (CHF) and type 2 diabetes, two of the most common and devastating chronic diseases in the world. The companys lead product, RT-100, is a treatment that delivers a therapeutic gene directly to the heart during a routine outpatient procedure and has the potential to increase heart function in millions of patients with CHF. The Renova Therapeutics pipeline also includes a groundbreaking gene therapy in preclinical stage for sufferers of type 2 diabetes, as well as a peptide infusion therapy for the treatment of acute decompensated heart failure. OUR MISSION: Creating transformational gene and peptide therapies that treat the most prevalent diseases to restore health and renew life OUR VISION: A future in which we are able to permanently treat chronic diseases with gene and peptide therapies
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month